As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm ...

Although Sarepta initially appeared to have avoided the worst possible outcome for Elevidys—a market withdrawal—thanks to the gene therapy’s new black box warning, the FDA is signaling stronger ...

Shares of Sarepta Therapeutics (NASDAQ:SRPT) fell in the premarket on Thursday following news regarding a clinical hold requested by the EU drug regulator, European Medicines Agency (EMA), on ...

The death of a patient treated with Sarepta's Duchenne muscular dystrophy (DMD) gene therapy Elevidys has played havoc with its share price – although analysts believe that its benefits still ...

Gene therapy developer Sarepta Therapeutics (NASDAQ:SRPT) lost ~20% on Tuesday to reach a new 52-week low after the company disclosed the death of a patient treated with Elevidys, its FDA-approved ...

Investing.com -- BMO Capital and Piper Sandler downgraded Sarepta Therapeutics (NASDAQ:SRPT) after the company reported a second death linked to its gene therapy Elevidys in a non-ambulatory ...

In March, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.

Sarepta Therapeutics, Inc.'s stock is downgraded to Hold due to underperformance, safety concerns with ELEVIDYS, and increased expenses, despite strong long-term fundamentals. Q1 2025 results show ...

This established skepticism from Dr. Prasad, even prior to the recent reports of liver failure deaths, suggests a likely reluctance to support Sarepta’s continued marketing of Elevidys.

Analyst Ratings Published06/18/2025, 02:53 AM Sarepta stock downgraded by TD Cowen on Elevidys approval concerns View all comments (0)0 SRPT -4.67% ...

Sarepta Therapeutics said Tuesday that a 16-year-old boy died after receiving Elevidys, its gene therapy for Duchenne muscular dystrophy, the first known death linked to the treatment.

Sarepta Therapeutics (SRPT) stock drops as the EU officials request a clinical hold on trials involving its gene therapy Elevidys after a patient death. Read more here.